DIAGNOSTIC VALUE OF SEROLOGICAL MARKERS OF RHEUMATOID ARTHRITIS

Rheumatoid arthritis (RA) is a classic autoimmune disease associated with the production of wide range of autoantibodies, and their detection has diagnostic and prognostic implication. The objective of this study was to estimate the diagnostic value of antibodies against modified citrullinated vimentin (AMCV) and nuclear antigen RA33 of the IgA rheumatoid factor (RF) versus the value of routinely used profile of autoantibodies in diagnostic work-up of RA. Material and methods. 253 patients with RA prehistory of varying duration were included into the study group. The control group was comprised of 92 patients, including patients with seronegative spondyloarthropathies and diffuse connective tissue diseases, as well as sex and age matched healthy controls. Serum levels of IgM and IgA RF, antibodies against cyclic citrullinated peptide (ACCP), ACMV, anti-keratin antibodies (AKA), antibodies against RA33 antigen (ARA33) and antinuclear factor (ANF) were measured in all patients and controls. Results and discussion. Diagnostic sensitivity of AMCV equaled 78%, ACCP — 77%, IgM RF — 71%, IgA RF — 43%, AKA — 43%, ARA33 — 31% and ANF — 31%. All anti-citrullinic antibodies (AKA, ACCP, ACMV) were significantly more commonly associated with IgM RF. Among RF and ACCP seronegative patients ACMV were found in 24% cases with 20 IU/Ml detection threshold, and in 21% — with 30 IU/Ml, allowing to increase diagnostic specificity of the test up to 91% with the increment of diagnostic threshold. Incidence of ARA33 was not significantly different among the RF and ACCP positive or negative subgroups, thus making ARA33 an independent RA marker. Specificity of this marker was 87,9%, thus making it inferior to RF and ACCP by a composite of diagnostic characteristics. Conclusions. Integrated measurement of ACMV and ARA33 is a rational approach at the second stage of serologic testing work-up in suspected cases of RA onset, when initial RF and ACCP tests were negative.

RA33, rheumatoid arthritis, immunologic diagnostics, autoantibodies, rheumatoid factor, anti-citrulline antibodies, antinuclear factor, biomarkers, RA33

1. <div><p>Соколова В.В., Лапин С.В., Москалев А.В. и др. Клиникоиммунологические взаимосвязи при раннем ревматоидном артрите. Мед. иммунол. 2007; 9(6): 635—42.</p><p>Чичасова Н.В., Каневская М.З., Имаметдинова Г.Р. и др. Отдаленные исходы ревматоидного артрита в зависимости от сроков начала терапии базисными противовоспалительными препаратами. Науч.-практич. ревматол. 2010; 3: 23-30.</p><p>Cush J.J. Early rheumatoid arthritis - is there a window of opportunity? J Rheumatol 2007; 80(Suppl.): 1-7.</p><p>Лапин С.В., Маслянский А.Л., Мазуров В.И. и др. Сравнительные характеристики специфических аутоантител при ревматоидном артрите. Тер. арх. 2005; 77(12): 53—9.</p><p>Лапин С.В., Тотолян A.A. Значение анифилаггриновых антител в серологической диагностике ревматоидного артрита: Обзор литературы. Клин. лаб. диагн. 2004; 11: 3-11.</p><p>Маслянский А.Л., Лапин С.В., Иливанова Е.П. и др. Антикератиновые антитела и антиперинуклеарный фактор являются маркером агрессивного течения ревматоидного артрита. Мед. иммунол. 2003; 5(5—6): 599—608.</p><p>Погожева Е.Ю., Смирнов А.В., Рапопорт И.Э. и др. Применение магнитно-резонансной томографии кистей при раннем ревматоидном артрите. Рос. мед. вестн. 2009; 14(2): 37—43.</p><p>Каратеев Д.Е., Александрова Е.Н., Демидова И.В. и др. Антицитруллиновые антитела и данные магнитно-резонансной томографии суставов кисти у больных ранним артритом. Тер. арх. 2008; 80(10): 72-6.</p><p>Keen H.I., Brown A.K., Wakefield R.J. et al. MRI and musculoskeletal ultrasonography as diagnostic tools in early arthritis. Rheum Dis Clin North Am 2005; 31(4): 699—714.</p><p>Александрова Е.Н., Чемерис Н.А., Каратеев Д.Е. и др. Антитела к циклическому цитруллинированному пептиду при ревматоидном артрите. Тер. арх. 2004; 76; 12: 64—8.</p><p>Беляева И.Б., Лапин С.В., Созина А.В. идр. Антитела к цитруллин-содержащим эпитопам в диагностике и прогнозировании течения раннего ревматоидного артрита. Мед. иммунол. 2007; 9(1): 77-84.</p><p>Emery P., Breedveld F.C., Dougados M. et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002; 61(4): 290—7.</p><p>Malakoutikhah M., Gomara M.J., Gomez-Puerta J.A. et al. The use of chimeric vimentin citrullinated peptides for the diagnosis of rheumatoid arthritis. J Med Chem 2011; 54(21): 7486—92.</p><p>Schneeberger E., Citera G., Heredia M. et al. Clinical significance of anti-Ro antibodies in rheumatoid arthritis. Clin Rheumatol 2008; 27(4): 517-9.</p><p>Pincus T., Sokka T. Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am 2009; 35(4): 731—4.</p><p>Aletaha D., Neogi T., Silman A.J. et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69(9): 1580—8.</p><p>Metz C.E. Basic principles of ROC analysis. Semin Nucl Med 1978; 8(4): 283-98.</p><p>Nell V.P., Machold K.P., Stamm T.A. et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005; 64(12): 1731—6.</p><p>Nell-Duxneuner V., Machold K., Stamm T. et al. Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study. Ann Rheum Dis 2010; 69(1): 169—74.</p></div><br />